Dr. Kolhouse and the Cowboy: A Western Mystery
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- The SELECT trial specifically enrolled individuals with a body mass index (BMI) of 27 or higher *and* established cardiovascular disease, such as a history of heart attack, stroke,...
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight - did not appear to offset this cardiovascular risk.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 1.5% | 1.2% |
| Nonfatal Stroke | 2.6% | 2.0% |
| Nonfatal Myocardial Infarction (Heart Attack) | 2.4% | 1.7% |
| Major Adverse Cardiovascular Events (MACE) | 6.5% | 4.9% |
Who is Affected? Understanding the Patient Population
The SELECT trial specifically enrolled individuals with a body mass index (BMI) of 27 or higher *and* established cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery disease.This is a crucial detail. The findings do *not* necessarily apply to individuals with obesity who do not have pre-existing heart conditions. Tho, given the prevalence of cardiovascular disease, a significant portion of the population seeking weight loss treatment may fall into this higher-risk category.
Furthermore, the average age of participants was 61, suggesting that older adults may be particularly vulnerable. The study also included a diverse population, with representation from various racial and ethnic groups, although further analysis is needed to determine if the increased risk varies across these groups.
Why Does This Happen? Potential Mechanisms at Play
The exact reasons for the increased cardiovascular risk are currently unknown and require further inquiry. Several hypotheses are being explored. one possibility is that rapid weight loss itself can induce metabolic stress and perhaps trigger cardiovascular events.Another is that semaglutide may have direct effects on the cardiovascular system that haven’t yet been fully understood. It’s also possible that the observed risk is related to underlying, undiagnosed cardiovascular issues in the study population.